VJHemOnc is committed to improving our service to you

EHA 2020 | Long-term safety of momelotinib for myelofibrosis

VJHemOnc is committed to improving our service to you

Claire Harrison

Claire Harrison, MD, DM, FRCP, FRCPath, of Guy’s and St Thomas’ NHS Foundation Trust, London, UK, outlines the long-term safety of momelotinib in myelofibrosis patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter